The University of California San Francisco (UCSF) is teaming up with Nektar Therapeutics to study the potential of NKTR-0165, an experimental antibody that activates the tumor necrosis factor receptor type 2 (TNFR2), to treat multiple sclerosis (MS). UCSF neurologist Stephen L. Hauser, MD, and his postdoctoral researcher Chaitrali Saha, PhD, will lead the project. The […]
The post UCSF, Nektar team to test potential of antibody therapy for MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com